Bionexus Gene Lab Stock Alpha and Beta Analysis
| BGLC Stock | USD 0.25 0.04 13.79% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BioNexus Gene Lab. It also helps investors analyze the systematic and unsystematic risks associated with investing in BioNexus Gene over a specified time horizon. Remember, high BioNexus Gene's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BioNexus Gene's market risk premium analysis include:
Beta 0.34 | Alpha (0.55) | Risk 3.84 | Sharpe Ratio (0.23) | Expected Return (0.89) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BioNexus |
BioNexus Gene Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BioNexus Gene market risk premium is the additional return an investor will receive from holding BioNexus Gene long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BioNexus Gene. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BioNexus Gene's performance over market.| α | -0.55 | β | 0.34 |
BioNexus Gene expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BioNexus Gene's Buy-and-hold return. Our buy-and-hold chart shows how BioNexus Gene performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BioNexus Gene Market Price Analysis
Market price analysis indicators help investors to evaluate how BioNexus Gene stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioNexus Gene shares will generate the highest return on investment. By understating and applying BioNexus Gene stock market price indicators, traders can identify BioNexus Gene position entry and exit signals to maximize returns.
BioNexus Gene Return and Market Media
The median price of BioNexus Gene for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 0.39 with a coefficient of variation of 11.52. The daily time series for the period is distributed with a sample standard deviation of 0.04, arithmetic mean of 0.39, and mean deviation of 0.04. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | BioNexus Gene Lab signs strategic partnership with Shenzhen Rongguang Group | 09/12/2024 |
2 | BioNexus Gene Lab Corp. Short Interest Up 670.5 percent in September | 09/27/2024 |
3 | BioNexus Gene Lab faces Nasdaq delisting over price rule By Investing.com - Investing.com Nigeria | 11/11/2024 |
About BioNexus Gene Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BioNexus or other stocks. Alpha measures the amount that position in BioNexus Gene Lab has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2022 | 2023 | 2024 (projected) | Dividend Yield | 6.0E-5 | 7.02E-4 | 6.32E-4 | 6.64E-4 | Price To Sales Ratio | 27.3 | 15.03 | 0.86 | 0.82 |
BioNexus Gene Upcoming Company Events
As portrayed in its financial statements, the presentation of BioNexus Gene's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNexus Gene's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of BioNexus Gene's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of BioNexus Gene. Please utilize our Beneish M Score to check the likelihood of BioNexus Gene's management manipulating its earnings.
| 29th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with BioNexus Gene
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out BioNexus Gene Backtesting, BioNexus Gene Valuation, BioNexus Gene Correlation, BioNexus Gene Hype Analysis, BioNexus Gene Volatility, BioNexus Gene History and analyze BioNexus Gene Performance. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.